Novo Nordisk (Germany) Buy Hold or Sell Recommendation
| NOVA Stock | EUR 100.00 0.50 0.50% |
Assuming the 90 days trading horizon and your complete indifference towards market risk, our recommendation regarding Novo Nordisk AS is 'Buy'. Macroaxis provides Novo Nordisk buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NOVA positions.
Check out Novo Nordisk Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Novo and provide practical buy, sell, or hold advice based on investors' constraints. Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Novo |
Execute Novo Nordisk Buy or Sell Advice
The Novo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novo Nordisk AS. Macroaxis does not own or have any residual interests in Novo Nordisk AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novo Nordisk's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Novo Nordisk Trading Alerts and Improvement Suggestions
| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 9.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novo Nordisk AS has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
Novo Nordisk Returns Distribution Density
The distribution of Novo Nordisk's historical returns is an attempt to chart the uncertainty of Novo Nordisk's future price movements. The chart of the probability distribution of Novo Nordisk daily returns describes the distribution of returns around its average expected value. We use Novo Nordisk AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novo Nordisk returns is essential to provide solid investment advice for Novo Nordisk.
| Mean Return | -0.33 | Value At Risk | -2.89 | Potential Upside | 2.39 | Standard Deviation | 1.72 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novo Nordisk historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novo Nordisk Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novo Nordisk or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novo Nordisk's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | 0.06 | |
σ | Overall volatility | 1.73 | |
Ir | Information ratio | -0.27 |
Novo Nordisk Volatility Alert
Novo Nordisk AS exhibits very low volatility with skewness of -0.09 and kurtosis of 0.85. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novo Nordisk's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novo Nordisk's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novo Nordisk Fundamentals Vs Peers
Comparing Novo Nordisk's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novo Nordisk's direct or indirect competition across all of the common fundamentals between Novo Nordisk and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novo Nordisk or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novo Nordisk's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novo Nordisk to competition |
| Fundamentals | Novo Nordisk | Peer Average |
| Return On Equity | 0.72 | -0.31 |
| Return On Asset | 0.22 | -0.14 |
| Profit Margin | 0.31 % | (1.27) % |
| Operating Margin | 0.43 % | (5.51) % |
| Current Valuation | 282.15 B | 16.62 B |
| Shares Outstanding | 2.25 B | 571.82 M |
| Shares Owned By Insiders | 0.01 % | 10.09 % |
| Shares Owned By Institutions | 8.34 % | 39.21 % |
| Price To Earning | 17.63 X | 28.72 X |
| Price To Book | 27.50 X | 9.51 X |
| Price To Sales | 1.68 X | 11.42 X |
| Revenue | 176.95 B | 9.43 B |
| Gross Profit | 148.51 B | 27.38 B |
| EBITDA | 76.8 B | 3.9 B |
| Net Income | 55.52 B | 570.98 M |
| Cash And Equivalents | 1.64 B | 2.7 B |
| Cash Per Share | 0.67 X | 5.01 X |
| Total Debt | 20.77 B | 5.32 B |
| Debt To Equity | 9.10 % | 48.70 % |
| Current Ratio | 0.96 X | 2.16 X |
| Book Value Per Share | 37.10 X | 1.93 K |
| Cash Flow From Operations | 78.89 B | 971.22 M |
| Earnings Per Share | 3.32 X | 3.12 X |
| Price To Earnings To Growth | 2.00 X | 4.89 X |
| Target Price | 116.88 | |
| Number Of Employees | 54.39 K | 18.84 K |
| Beta | 0.33 | -0.15 |
| Market Capitalization | 303.37 B | 19.03 B |
| Total Asset | 241.26 B | 29.47 B |
| Z Score | 8.4 | 8.72 |
| Annual Yield | 0.01 % | |
| Five Year Return | 2.26 % | |
| Net Asset | 241.26 B |
Novo Nordisk Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Novo Nordisk Buy or Sell Advice
When is the right time to buy or sell Novo Nordisk AS? Buying financial instruments such as Novo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novo Nordisk in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Novo Nordisk Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.